Fibrosing cholestatic hepatitis

Fibrosing cholestatic hepatitis is a severe manifestation of chronic HCV infection in which immunosuppression after kidney transplantation can permit a sharp rise in viral replication and rapidly damaging cholestatic liver disease. It is uncommon, but its course may include diffuse fibrosis, liver failure, and death; the condition therefore stands at the dangerous intersection of viral burden, transplantation, and the need to preserve a kidney allograft.

Definition and Clinical Setting

Fibrosing cholestatic hepatitis is described principally in HCV-infected kidney transplant recipients receiving powerful immunosuppression. The broader transplant setting can accelerate HCV replication and lead to serious liver injury, including cirrhosis and Fibrosing cholestatic hepatitis. This risk is especially important in recipients who remain HCV RNA positive at transplantation, although the condition may also appear in patients whose infection was not recognized by antibody testing at the time of the procedure.

The condition is not simply a laboratory designation. It is identified through a combination of rapidly evolving liver dysfunction, high serum HCV RNA, and characteristic liver histology. The reported pathological pattern includes diffuse fibrosis, leukocyte infiltration, and varying degrees of cholestasis; typical signs of HCV hepatitis may be conspicuous in only some patients. This distinction matters because ordinary biochemical abnormalities can underestimate the severity of the underlying process.

Early Case Series After Kidney Transplantation

Muñoz De Bustillo and colleagues first described Fibrosing cholestatic hepatitis in HCV-positive kidney transplant recipients. Among 259 HCV-infected transplant recipients, four patients, or 1.5%, developed the condition. All were receiving steroids, cyclosporine, and azathioprine. The syndrome appeared relatively soon after transplantation, at a mean of 11.5 months, and was accompanied by high HCV RNA levels.

Three of the four patients developed hyperbilirubinemia, with bilirubin reaching 6.5 mg/dl, together with markedly increased alkaline phosphatase levels ranging from 428 to 859 IU/l. All four had very high gamma-glutamyl transferase concentrations, ranging from 639 to 4,270 IU/l, while aspartate aminotransferase and alanine aminotransferase abnormalities were only mild. The mismatch between striking cholestatic injury and modest aminotransferase elevation is one of the clinically important features of the reported syndrome.

The consequences were grave. Two patients developed subfulminant liver failure and died two and three months after biopsy. Another patient with hepatic failure underwent liver transplantation. The fourth remained alive on dialysis while awaiting combined liver and kidney transplantation. These outcomes show why Fibrosing cholestatic hepatitis is treated as a life-threatening complication rather than as a slowly progressive form of post-transplant liver disease.

A second small series, reported by Delladetsima and colleagues, involved four cases among 73 HCV-infected kidney transplant recipients. Liver dysfunction appeared only one to four months after transplantation, and histological diagnosis followed three to eleven months later. Three patients developed a progressive cholestatic syndrome, whereas the fourth had only slightly increased alanine aminotransferase and gamma-glutamyl transferase levels. Histology showed a characteristic pattern in two patients and changes compatible with early Fibrosing cholestatic hepatitis in the other two.

All four patients in that series were anti-HCV negative at transplantation, yet all were HCV RNA positive at the time of the first liver biopsy and had high circulating viral loads. Two subsequently seroconverted, after three and 31 months respectively. HCV genotype was 1b in three patients and 3a in one. After diagnosis, immunosuppression was drastically reduced; nevertheless, two patients died from sepsis and liver failure at 16 and 18 months after transplantation. The patients who seroconverted showed marked improvement in liver disease, confirmed histologically in one case, and two similar patients in another report were successfully treated with interferon-alpha.

Relation to Post-Transplant HCV Management

The possibility of Fibrosing cholestatic hepatitis is one reason clinicians distinguish patients who require treatment from the larger group of HCV RNA-positive kidney recipients whose liver histology remains stable. Sequential biopsy studies found that kidney transplantation does not invariably accelerate liver injury: in one series, 77% of recipients who underwent follow-up biopsies had stable or improved histology, while another study measured an overall fibrosis progression rate of 0.09 ± 0.03 Metavir units per year. Yet approximately 20% of patients in one cohort developed severe fibrosis, and the harm attributable to HCV after more than ten years was estimated to affect fewer than half of recipients.

These findings support surveillance rather than indiscriminate post-transplant antiviral treatment. Repeat liver biopsies can identify recipients who develop severe fibrosis, while clinical deterioration can identify those with immediately dangerous disease. Fibrosing cholestatic hepatitis belongs to the latter group: HCV RNA-positive recipients who develop this life-threatening condition may benefit from antiviral therapy, with the aim of improving their chance of survival.

Treatment decisions are constrained by the transplant allograft. Interferon-alpha alone has been associated with a very low sustained virologic response and poor tolerance, particularly because it can induce acute rejection. Combining interferon-alpha with ribavirin produces a higher sustained virologic response, but randomized trials evaluating its safety for kidney allograft function are lacking. Ribavirin alone, or ribavirin combined with amantadine, does not produce a sustained virologic response, although ribavirin may improve HCV-related proteinuria. Consequently, eradication of HCV before kidney transplantation, while the patient remains on dialysis, is generally preferable whenever feasible; after transplantation, interferon-alpha plus ribavirin is reserved for selected situations such as rapidly progressive cirrhosis, Fibrosing cholestatic hepatitis, or de novo cryoglobulinemic glomerulonephritis in the allograft.

Broader Significance

Fibrosing cholestatic hepatitis exposes the tension built into kidney transplantation for patients with HCV infection. Immunosuppression protects the transplanted kidney but can sharply increase viral replication, while antiviral treatment may control the virus yet threaten the allograft through rejection. The condition therefore turns a chronic infection into an urgent therapeutic conflict involving liver failure, sepsis, dialysis, and the possibility of combined liver and kidney transplantation.

Its recognition also reinforces the need to separate anti-HCV status from active infection. Chronic HCV infection is established by both anti-HCV antibodies and detectable HCV RNA; antibody negativity at transplantation did not exclude the aggressive disease described in the second case series. In this setting, viral RNA, serial biochemical assessment, histology, and the clinical tempo of cholestasis together provide the more meaningful picture. Fibrosing cholestatic hepatitis is thus both a pathological syndrome and a warning about the limits of relying on serology alone in immunosuppressed transplant recipients.